In the diuretic phase of renal failure, which of the following happens?

Choice A rationale:

Electrolytes do not consistently improve during the diuretic phase of renal failure. While urine output increases, the kidneys' ability to regulate electrolytes may still be impaired. Electrolyte imbalances, such as hyperkalemia, hyponatremia, and hyperphosphatemia, can persist or even worsen during this phase.

Close monitoring of electrolytes is crucial to guide appropriate interventions, such as electrolyte replacement or restriction.

Choice B rationale:

Urine output (UO) does not remain unchanged during the diuretic phase. It is a defining characteristic of this phase that urine output increases, often significantly. This increase in urine output is a result of the recovering kidney tubules' ability to excrete fluid and waste products.

Choice C rationale:

Urine output (UO) increases in the diuretic phase of renal failure. This is a key feature that distinguishes this phase from the oliguric phase, which is characterized by decreased urine output. The increase in urine output is typically a sign of kidney function recovery. However, it is important to note that the increase in urine output does not necessarily mean that kidney function has fully recovered.

Choice D rationale:

Oxygenation does not typically worsen during the diuretic phase of renal failure. In fact, oxygenation may improve as fluid overload is resolved and pulmonary edema decreases. However, patients with underlying respiratory conditions or those who experience rapid fluid shifts may still require respiratory support.

Choice A rationale:

Trisomy 21, also known as Down syndrome, is a genetic condition caused by the presence of an extra copy of chromosome 21.

The nuchal translucency test (NT) is a non-invasive ultrasound screening test that measures the thickness of the fluid-filled space at the back of a developing baby's neck.

Evidence suggests that fetuses with Down syndrome tend to have increased fluid accumulation in this area, resulting in a larger-than-average nuchal translucency measurement.

Therefore, an increased NT measurement can be a marker for an increased risk of Down syndrome.

It's important to emphasize that the NT test is a screening tool, not a diagnostic test.

This means it can only indicate an increased risk of Down syndrome; it cannot definitively diagnose the condition.

To confirm a diagnosis, further testing, such as chorionic villus sampling (CVS) or amniocentesis, is required.

Choice B rationale:

Neural tube defects (NTDs) are birth defects that affect the brain, spine, or spinal cord.

The most common NTDs are spina bifida and anencephaly.

The NT test is not a diagnostic test for NTDs, although it might detect some cases of open spina bifida.

However, it's not specifically designed for this purpose, and other tests, such as alpha-fetoprotein (AFP) screening or detailed ultrasound, are more reliable for diagnosing NTDs.

Choice C rationale:

The NT test is typically performed in the first trimester of pregnancy, between 11 and 14 weeks gestation.

It's not available in the second trimester because the nuchal translucency measurement becomes less reliable after this point in pregnancy.

Choice D rationale:

A nuchal translucency measurement of 3mm or less is generally considered normal.

Measurements greater than 3mm are associated with an increased risk of Down syndrome and other chromosomal abnormalities.

The higher the measurement, the greater the risk.